Table 1.

Efficacy results in the adjuvant trastuzumab trials

RegimenMedian follow-up (y)Patients enrolledDisease-free survival, HR (95% CI)Overall survival, HR (95% CI)Reference
HERAChemo→observation21,698(13)
Chemo→H × 1 y1,7030.63 (0.53-0.75), P < 0.0001*0.63 (0.45-0.87), P = 0.0051*
Chemo→H × 2 y1,701NRNR
NCCTG 9831AC→P→observation819(12)
AC→P→H2.9981
AC→PH8140.48 (0.41-0.57), P < 0.0001*0.65 (0.51-0.84), P = 0.0007
NSABP 31AC→P→observation1,024
AC→PH1,019
BCIRG 006AC→T→observation31,072(14)
AC→TH1,0760.61 (0.48-0.76), P < 0.00010.59 (0.42-0.85), P = 0.004
TCH1,0740.67 (0.54-0.83), P = 0.000030.66 (0.47-0.93), P = 0.017
FINHERV→FEC or T→FEC3116(13)
VH→FEC or TH→FEC1160.42 (0.21-0.83), P = 0.010.41 (0.16-1.08), P = 0.07
PACS 04FEC or ET→observation4268(16)
FEC→H or ET→H2600.86 (0.61-1.22), P = 0.411.27 (0.68-2.38)
  • Abbreviations: Chemo, chemotherapy; H, trastuzumab; AC, doxorubicin/cyclophosphamide; P, paclitaxel; PH, paclitaxel/trastuzumab; T, docetaxel; TH, docetaxel/trastuzumab; TCH, docetaxel/carboplatin/trastuzumab; VH, vinorelbine/trastuzumab; FEC, 5-fluoruracil/epirubicin/cyclophosphamide; V, vinorelbine; ET, epirubicin/docetaxel; HR, hazard ratio; 95% CI, 95% confidence interval; NR, not reported.

  • * Censored population.

  • Recurrence-free survival.